江苏慧聚药业

Jiangsu Crystal Pharmaceutical is a prominent Chinese Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) manufacturer. Founded in 2000, the company specializes in providing integrated CMC services, including process chemistry research, analytical development, and commercial-scale production of small molecule APIs and intermediates. They operate multiple state-of-the-art facilities that comply with international GMP standards, serving a global clientele across the United States, Europe, and Asia. Their product portfolio supports diverse therapeutic areas such as oncology, cardiovascular health, and the central nervous system. The company is recognized for its technical expertise in complex chemical transformations, including high-pressure hydrogenation and chiral synthesis. With a strong track record of successful regulatory inspections by the FDA and EMA, they are a trusted partner for both innovator and generic pharmaceutical companies.